Press Releases Keyword Search Year None202420232022202120202019201820172016201520142013 July 31, 2024 Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update June 14, 2024 Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress May 14, 2024 Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June May 10, 2024 Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting May 8, 2024 Editas Medicine Announces First Quarter 2024 Results and Business Updates May 2, 2024 Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events May 1, 2024 Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration April 22, 2024 Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting February 28, 2024 Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates February 21, 2024 Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last »
July 31, 2024 Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
June 14, 2024 Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
May 14, 2024 Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
May 10, 2024 Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
May 2, 2024 Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
April 22, 2024 Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
February 28, 2024 Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
February 21, 2024 Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
